Drug Development Core

项目总结/摘要 药物开发中心（DDC）直接支持UWCCC的使命，即通过以下方式开发创新疗法： 提供具有成本效益的，尖端的，高通量筛选（HTS）服务;药物化学和铅 优化服务;以及支持临床试验的药代动力学（PK）和药效学（PD）服务。 这些服务由广泛的专业知识、最先进的设备和尖端的 用于分析设计、合成化学、计算化学、分析化学和 药理学通过一套以任务为中心的具体目标，DDC将实现对以下方面的高水平支持： UWCCC成员。具体目标1：通过提供UWCCC成员药物开发研究 化合物发现、药物化学、计算化学的专业知识和资源， 化学预防和抗癌剂的药理学。具体目标1的主要目标是提供 充分支持UWCCC用户所需的专业知识、设备和计算工具。具体来说，DDC 工作人员将在实验设计、数据采集和数据分析方面提供建议，以确保实验的严谨性和可重复性。 以具有成本效益的方式进行高影响力药物开发研究。影响：13个HTS活动，10项专利， 10个毒品线索具体目标2：通过提供专业知识， 评价研究药物的药代动力学和药效学特性所需的基础设施。 为达致这个目标，部门发展中心会为病人样本储存提供一个稳健及安全的数据库系统， 记录所有样本。此外，DDC将提供分析专业知识，以正确采样，分析， 定量来自患者组织的药物和药物代谢物。这些服务对于UWCCC参与以下活动至关重要： NCI赞助的UM 1项目，NCI的国家临床试验网络（NCTN），以及行业赞助的临床试验。 审判在本资助期内，发展局资助了394项大学妇儿保育中心研究，包括209项非癌症研究 赞助的研究。考虑到发展治疗学项目提出的扩大临床试验的建议， 我们预计在下一个资助期内，这一数字会增加。具体目标3：培训UWCCC成员， 工作人员和学生在药物开发过程中和生产性使用国家的最先进的设备 来实现他们的研究目标。经验丰富的DDC工作人员将确保设备得到良好的维护， 高度可靠，可供UWCCC成员，他们的工作人员和学生在24/7的基础上。另夕h DDC工作人员将定期向PI、博士后和学员介绍研究和新技术。DDC已经 在目前的资助期间，培训了168名与UWCCC有关的用户。通过这些具体 DDC不仅支持UWCCC的使命，而且还为UWCCC成员提供直接支持 以最大限度地发挥其影响，并进一步推进尖端癌症研究。DDC支持109个唯一UWCCC 在2017-2021年期间，所有6个UWCCC科学计划和113个成员出版物的计划成员。

PROJECT SUMMARY / ABSTRACT The Drug Development Core (DDC) directly supports the UWCCC mission to develop innovative therapies by providing cost-effective, cutting-edge, high-throughput screening (HTS) services; medicinal chemistry and lead optimization services; and pharmacokinetic (PK) and pharmacodynamic (PD) services to support clinical trials. These services are supported by extensive expertise, state-of-the-art equipment, and cutting-edge computational tools for assay design, synthetic chemistry, computational chemistry, analytical chemistry, and pharmacology. Through a mission-centered set of specific aims, the DDC will achieve a high level of support for UWCCC members. Specific Aim 1: Advance UWCCC member drug development research by providing expertise and resources for compound discovery, medicinal chemistry, computational chemistry, and pharmacology of chemoprevention and anticancer agents. The primary goal of Specific Aim 1 is to provide the expertise, equipment, and computational tools required to fully enable UWCCC users. Specifically, the DDC staff will advise on experimental design, data acquisition, and data analysis to ensure rigor and reproducibility of high impact drug development research in a cost-effective manner. Impact: 13 HTS campaigns, 10 patents, and 10 drug leads. Specific Aim 2: Support clinical trials conducted at UWCCC by providing the expertise and infrastructure needed to evaluate the pharmacokinetic and pharmacodynamic properties of study drugs. To achieve this aim, the DDC will provide patient sample storage with a robust and secure database system to document all samples. Additionally, the DDC will provide analytical expertise to properly sample, analyze, and quantify drugs and drug metabolites from patient tissues. These services are critical to UWCCC participation in NCI sponsored UM1 programs, NCI’s National Clinical Trials Network (NCTN), and industry sponsored clinical trials. In the current funding period, the DDC provided support for 394 UWCCC studies including 209 NCI sponsored studies. Given the proposed expansion of clinical trials by the Developmental Therapeutics program, we predict this number to increase in the next funding period. Specific Aim 3: Train UWCCC members, their staff, and students in drug development processes and the productive use of state-of-the-art equipment to meet their research goals. The highly experienced DDC staff will ensure that equipment is well maintained, highly reliable, and available for UWCCC members, their staff, and students on a 24/7 basis. Additionally, the DDC staff will routinely present studies and new technologies to PI’s, postdocs, and trainees. The DDC has trained over 168 users associated with the UWCCC during the current funding period. Through these Specific Aims, DDC will not only support the mission of the UWCCC but also provide direct support to UWCCC members to maximize their impact and further advance cutting-edge cancer research. DDC supported 109 unique UWCCC program members across all 6 UWCCC scientific programs and 113 member publications during 2017-2021.